Cytokinetics Receives FDA Approval for Myqorzo; Truist Sets $84 Target
Cytokinetics Incorporated (NASDAQ: CYTK) received U.S. Food and Drug Administration approval for Myqorzo (aficamten) on December 22, 2025. The drug is indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and reduce symptoms.
Following the regulatory milestone, Srikripa Devarakonda from Truist Financial established a price target of $84 for the biopharmaceutical company. This target implies a potential upside of approximately 24.8% from the trading price of $67.33 recorded earlier in the session. Shares of CYTK rose 7.7% or $4.85 to reach $67.57 on December 22, 2025, with a daily trading range between $63.18 and $70.98.
Myqorzo functions as an allosteric and reversible inhibitor of cardiac myosin motor activity. It aims to reduce cardiac contractility and left ventricular outflow tract obstruction. The FDA approval includes a Boxed WARNING regarding the risk of heart failure, which requires patients to undergo regular echocardiogram assessments to monitor ejection fraction levels.
Market data for Cytokinetics on December 22, 2025, includes the following:
- Market capitalization of approximately $8.04B USD.
- Daily trading volume of 5,494,603 shares on the NASDAQ exchange.
- A 52-week price range between $29.31 and $70.98.
The company remains focused on muscle biology-driven treatments. Additional information regarding the company is available through its CYTK and CYTK. Investors can also review the CYTK and the CYTK for further context on financial performance and ownership structure.
Cytokinetics, Incorporated (CYTK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.